PL361518A1 - Zastosowanie substancji oraz kompozycja farmaceutyczna - Google Patents

Zastosowanie substancji oraz kompozycja farmaceutyczna

Info

Publication number
PL361518A1
PL361518A1 PL03361518A PL36151803A PL361518A1 PL 361518 A1 PL361518 A1 PL 361518A1 PL 03361518 A PL03361518 A PL 03361518A PL 36151803 A PL36151803 A PL 36151803A PL 361518 A1 PL361518 A1 PL 361518A1
Authority
PL
Poland
Prior art keywords
substance
application
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
PL03361518A
Other languages
English (en)
Other versions
PL209644B1 (pl
Inventor
Luca Rampoldi
Luca Pirrone
Sarah Faccin
Alessandro Grassano
Giovanni Gurrieri
Original Assignee
Zambon Group S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27638551&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL361518(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zambon Group S.P.A. filed Critical Zambon Group S.P.A.
Publication of PL361518A1 publication Critical patent/PL361518A1/pl
Publication of PL209644B1 publication Critical patent/PL209644B1/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/665Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/42Phosphorus; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
PL361518A 2002-08-01 2003-07-31 Zastosowanie substancji oraz kompozycja farmaceutyczna PL209644B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT001725A ITMI20021725A1 (it) 2002-08-01 2002-08-01 Composizioni farmaceutiche ad attivita' antibiotica.

Publications (2)

Publication Number Publication Date
PL361518A1 true PL361518A1 (pl) 2004-02-09
PL209644B1 PL209644B1 (pl) 2011-09-30

Family

ID=27638551

Family Applications (1)

Application Number Title Priority Date Filing Date
PL361518A PL209644B1 (pl) 2002-08-01 2003-07-31 Zastosowanie substancji oraz kompozycja farmaceutyczna

Country Status (29)

Country Link
US (1) US7303755B2 (pl)
JP (1) JP4395338B2 (pl)
KR (1) KR100966977B1 (pl)
AT (1) AT500521B1 (pl)
BE (1) BE1017903A3 (pl)
BR (1) BRPI0302496C1 (pl)
CA (1) CA2434927C (pl)
CH (1) CH696718A5 (pl)
CO (1) CO5480297A1 (pl)
CZ (1) CZ305023B6 (pl)
DE (1) DE10334820B4 (pl)
DK (1) DK178348B1 (pl)
ES (1) ES2224869B1 (pl)
FI (1) FI120080B (pl)
FR (1) FR2852845B1 (pl)
GR (1) GR20030100300A (pl)
HR (1) HRP20030618B1 (pl)
HU (1) HU230575B1 (pl)
IL (1) IL156615A (pl)
IT (1) ITMI20021725A1 (pl)
NL (1) NL1023790C2 (pl)
PL (1) PL209644B1 (pl)
PT (1) PT102995B (pl)
RU (1) RU2333000C2 (pl)
SE (1) SE527466C2 (pl)
SI (1) SI21259B (pl)
SK (1) SK287201B6 (pl)
TR (1) TR200301248A2 (pl)
ZA (1) ZA200305040B (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE740685C (de) * 1941-04-11 1943-10-26 Voigt & Haeffner Ag Viertakt-Regelschalter fuer Parallel-, Einzel- und Reihenschaltung von Heizwiderstaenden
ES2244333B1 (es) * 2004-05-18 2006-08-01 Simbec Iberica, Sl Preparado farmaceutico oral de fosfomicina estable y apto para diabeticos.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN107028924A (zh) 2009-10-02 2017-08-11 勃林格殷格翰国际有限公司 包含bi‑1356和二甲双胍的药物组合物
EA021876B1 (ru) * 2010-09-20 2015-09-30 ЛИМОНОВ, Виктор Львович Фармацевтическая композиция антимикробного и противовоспалительного действия для парентерального введения, способ ее получения
ES2385158B1 (es) * 2010-12-24 2013-05-28 Arafarma Group, S.A. Composición farmacéutica de fosfomicina
CN102579466A (zh) * 2011-01-10 2012-07-18 王乐 一种磷霉素或磷霉素精氨酸盐与精氨酸的组合物
US8604078B2 (en) * 2011-04-06 2013-12-10 Carlos Picornell Darder Fosfomycin pharmaceutical composition
US20140323443A1 (en) * 2013-04-30 2014-10-30 Fresenius Kabi Usa, Llc Tigecycline formulations
ITTO20130839A1 (it) * 2013-10-16 2015-04-17 C & G Farmaceutici S R L Composizione a base di fosfomicina trometamolo
DE102014218913A1 (de) 2014-09-19 2016-03-24 Heraeus Medical Gmbh Verfahren zur Herstellung eines antibiotischen Polymehtylmethacrylat-Knochenzementpulvers und ein antibiotisches Polymethtylmethacrylat-Knochenzementpulver
CN104546689B (zh) * 2015-01-07 2019-01-25 同方药业集团有限公司 一种含有甲硝唑的药物组合物
US20180360855A1 (en) 2015-12-25 2018-12-20 Yusuf Toktamis ÖGÜN The formulation comprising phosphomycine and ascorbic acid for the treatment of bacterial urinary system infections
CA3147662A1 (en) 2021-02-10 2022-08-10 Labiana Health, S.L. New fosfomycin tablet formulations

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3852434A (en) 1970-09-11 1974-12-03 Merck & Co Inc Potentiation of ({31 ) cis-1,2-epoxypropyl)phosphonic acid and analogues thereof
IT1161974B (it) 1978-02-02 1987-03-18 Italchemi Spa Derivti dell acido cis.i 2 epossipropilfosfonico loro procedimento di preparazione e composizioni farmaceutiche che li contengono
IT1112282B (it) 1978-07-19 1986-01-13 Zambon Spa Bis-(2-ammonio-2-idrossimetil-1,3-propandiolo)(2r-cis)-(3-metilossiranil)fosfonato
IT1124610B (it) 1979-10-18 1986-05-07 Zambo Spa Mono(2-ammonio-2-idrossimetil-1,3-propandiolo) (2r-cis)-(o-metilossiranil)fosfonato
JPS59104326A (ja) * 1982-12-04 1984-06-16 Toyo Jozo Co Ltd マクロライド抗生物質の安定な経口用製剤および安定化法
CH660305A5 (de) 1984-10-05 1987-04-15 Schering Spa Wasserloesliche pharmazeutische zusammensetzungen auf der basis von salzen der (-)cis-1,2-epoxypropylphosphonsaeure mit aminosaeuren.
EP0390930B1 (en) * 1988-09-26 1993-03-03 Teijin Limited Stable aqueous preparation of active vitamin d 3
US5191094A (en) 1989-07-27 1993-03-02 Zambon Group S.P.A. Mono (2-ammonium-2-hydroxymethyl-1,3-propanediol) (2R,cis)-1,2-epoxypropyl-phosphonate with improved characteristics of stability and processing
IT1231013B (it) * 1989-07-27 1991-11-08 Zambon Spa Mono (2 ammonio 2 idrossimetil 1,3 propandiolo)(2r,cis) 1,2 epossipropil fosfonato avente migliorate caratteristiche di stabilita' e lavorabilita'.
IT1244543B (it) 1991-02-01 1994-07-15 La Fa Re Srl Uso topico della fosfomicina e dei suoi sali nella terapia delle infezioni vaginali e/o uretrali
FR2690340B1 (fr) 1992-04-24 1995-02-24 Scr Newmed Nouveau procédé de stabilisation des préparations pharmaceutiques liquides et les compositions pharmaceutiques ainsi stabilisées en résultant.
CA2091152C (en) 1993-03-05 2005-05-03 Kirsten Westesen Solid lipid particles, particles of bioactive agents and methods for the manfuacture and use thereof
DE4327063A1 (de) * 1993-08-12 1995-02-16 Kirsten Dr Westesen Ubidecarenon-Partikel mit modifizierten physikochemischen Eigenschaften
CA2153553A1 (en) * 1994-07-13 1996-01-14 Hidekazu Suzuki Stable lipid emulsion
JPH09183730A (ja) * 1995-05-10 1997-07-15 Meiji Seika Kaisha Ltd ホスホマイシン鏡像異性体を含んでなる医薬
DE19712565A1 (de) 1997-03-25 1998-10-01 Thomas W Dr Stief Arzneimittel auf der Basis eines Singulett-Sauerstoff erzeugenden Agenzes
PL218223B1 (pl) * 2000-06-21 2014-10-31 Cubist Pharmaceuticals Kompozycja farmaceutyczna do doustnego dostarczania cefalosporyny
US6699505B2 (en) * 2000-10-17 2004-03-02 Massachusetts Institute Of Technology Method of increasing the efficacy of antibiotics by compexing with cyclodextrins
US7378408B2 (en) 2001-11-30 2008-05-27 Pfizer Inc. Methods of treatment and formulations of cephalosporin
TW200403240A (en) * 2002-06-28 2004-03-01 Upjohn Co Difluorothioacetamides of oxazolidinones as antibacterial agents

Also Published As

Publication number Publication date
GR20030100300A (el) 2004-04-22
JP4395338B2 (ja) 2010-01-06
HU230575B1 (hu) 2017-02-28
TR200301248A2 (tr) 2004-02-23
SE0302129D0 (sv) 2003-07-25
FR2852845A1 (fr) 2004-10-01
PT102995B (pt) 2004-07-30
BRPI0302496C1 (pt) 2021-05-25
KR100966977B1 (ko) 2010-06-30
AT500521A1 (de) 2006-01-15
DE10334820A1 (de) 2004-03-11
SE0302129L (sv) 2004-02-02
SK287201B6 (sk) 2010-03-08
FR2852845B1 (fr) 2006-01-06
PT102995A (pt) 2004-02-27
SE527466C2 (sv) 2006-03-14
BE1017903A3 (fr) 2009-11-03
US7303755B2 (en) 2007-12-04
PL209644B1 (pl) 2011-09-30
FI120080B (fi) 2009-06-30
KR20040012569A (ko) 2004-02-11
BRPI0302496B8 (pt) 2016-09-13
SK9762003A3 (en) 2004-02-03
JP2004067682A (ja) 2004-03-04
DK178348B1 (da) 2016-01-04
ZA200305040B (en) 2004-05-11
NL1023790A1 (nl) 2004-02-03
ES2224869A1 (es) 2005-03-01
CA2434927C (en) 2011-10-18
IL156615A0 (en) 2004-01-04
CA2434927A1 (en) 2004-02-01
CZ305023B6 (cs) 2015-04-01
US20040022866A1 (en) 2004-02-05
RU2003124299A (ru) 2005-01-20
RU2333000C2 (ru) 2008-09-10
BR0302496A (pt) 2004-08-24
SI21259A (sl) 2004-02-29
IL156615A (en) 2008-11-26
HUP0302441A2 (hu) 2005-07-28
FI20031078A0 (fi) 2003-07-16
NL1023790C2 (nl) 2004-03-10
HRP20030618A2 (en) 2004-04-30
FI20031078A (fi) 2004-02-02
CO5480297A1 (es) 2005-01-28
BRPI0302496B1 (pt) 2015-07-28
AT500521B1 (de) 2007-11-15
CZ20032096A3 (cs) 2004-03-17
DE10334820B4 (de) 2020-02-06
ES2224869B1 (es) 2007-07-01
HU0302441D0 (en) 2003-09-29
CH696718A5 (it) 2007-10-31
DK200301097A (da) 2004-02-02
ITMI20021725A1 (it) 2002-10-31
HRP20030618B1 (en) 2011-10-31
SI21259B (sl) 2012-12-31

Similar Documents

Publication Publication Date Title
IL173639A0 (en) Ppar-activating compound and pharmaceutical composition containing same
PL354168A1 (pl) Sposób leczenia zaburzesigma metabolicznych, zwłasSposób leczenia zaburzesigma metabolicznych, zwłaszcza cukrzycy albo chorób lub stanów związanych zzcza cukrzycy albo chorób lub stanów związanych zcukrzycącukrzycą
TWI346558B (en) Pharmaceutical composition for chronic treatment of inflammation and use thereof
PL375860A1 (pl) Chemiczne związki
IL164987A0 (en) Proline derivatives and pharmaceutical compositions containing
HUP0401711A3 (en) N-heterocyclic inhibitors of tnf-alpha and pharmaceutical compositions containing them
HK1164133A1 (en) Nasal pharmaceutical formulations and methods of using the same
HK1088543A1 (en) Pharmaceutical compositions and dosage forms of thalidomide
EP1594467A4 (en) MISUSE OF PHARMACEUTICAL COMPOSITIONS OF OPIOIDES AND OTHER MEDICAMENTS
IL166108A0 (en) Novel compounds pharmaceutical compositions containing same and methods of use for same
HK1091727A1 (en) Nasal pharmaceutical formulations and methods of using the same
HK1082677A1 (en) Androgen pharmaceutical composition and use for manufacture of medicament
IL164022A0 (en) Phosphate derivatives of fluoroxindole and pharmaceutical compositions containing the same
IL174144A0 (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
IL164217A0 (en) Pharmaceutical compositions containing water-soluble propofol and methods of administering same
IL163868A (en) Hemiasterlin derivatives and pharmaceutical compositions comprising them
IL166621A0 (en) Polymorph of n-methyl-n-(3-ä-3-Ä2-thienylcarbonylÜ-pyrazol-Ä1,5-alphaÜpyrimidin-7-ylüacetamide and pharmaceutical compositions containing the same
PL361518A1 (pl) Zastosowanie substancji oraz kompozycja farmaceutyczna
HK1066459A1 (en) Pharmaceutical dosage form and method of making
IL176077A0 (en) 1-n-phenyl-amino-1h-imidazole derivatives and pharmaceutical compositions containing them
IL166054A0 (en) Novel compounds pharmaceutical compositions containing same and methods of use for same
GB0608398D0 (en) Pharmaceutical composition and method of using same
IL163959A (en) Derivatives of phenyl-sulfonylamino- benzoic acid and pharmaceutical compositions comprising them
HK1078469A1 (en) Pharmaceutical and cosmetic compositions comprising plgf-1
AU2003252493A1 (en) Pharmaceutical composition containing decoy and method of using the same